Lucid Diagnostics (LUCD) CMO holds 650K shares including restricted stock

Rhea-AI Filing Summary

Lucid Diagnostics Inc. reported initial share ownership for Chief Medical Officer Lee Victoria Tou-ho. The filing shows direct ownership of 650,000 shares of common stock, including restricted stock granted under the company’s 2018 Equity Plan that vests over several future dates and can be forfeited if service requirements are not met.

The restricted stock grants consist of 200,000 shares awarded November 6, 2023 vesting on November 6, 2026, 150,000 shares awarded February 20, 2025 vesting on May 20, 2028, and 300,000 shares awarded February 20, 2026 vesting on May 20, 2029, all subject to continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lee Victoria Tou-ho

Role Chief Medical Officer

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 650,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Common stock holdings: 650,000 shares Restricted stock grant 1: 200,000 shares Restricted stock grant 2: 150,000 shares +1 more

4 metrics

Common stock holdings 650,000 shares Direct ownership reported by Chief Medical Officer

Restricted stock grant 1 200,000 shares Awarded November 6, 2023; single vest date November 6, 2026

Restricted stock grant 2 150,000 shares Awarded February 20, 2025; single vest date May 20, 2028

Restricted stock grant 3 300,000 shares Awarded February 20, 2026; single vest date May 20, 2029

Key Terms

restricted stock, 2018 Equity Plan, vesting schedule, forfeiture

4 terms

restricted stock financial

"Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

2018 Equity Plan financial

"granted to the reporting person under the Issuer's 2018 Equity Plan"

vesting schedule financial

"with the following grant and vesting schedule: 200,000 (awarded November 6, 2023)..."

A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.

forfeiture financial

"Such restricted stock are subject to forfeiture if the requisite service period is not completed."

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lee Victoria Tou-ho

(Last) (First) (Middle)

360 MADISON AVENUE

25TH FLOOR

(Street)

NEW YORK NEW YORK 10017

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/23/2026

3. Issuer Name and Ticker or Trading Symbol
Lucid Diagnostics Inc. [ LUCD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	650,000(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with the following grant and vesting schedule: 200,000 (awarded November 6, 2023) that has a single vest date of November 6, 2026; 150,000 (awarded February 20, 2025) that has a single vest date of May 20, 2028; 300,000 (awarded February 20, 2026) that has a single vest date of May 20, 2029. Such restricted stock are subject to forfeiture if the requisite service period is not completed.

	/s/ Michael A. Gordon, by power of attorney	04/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

How many Lucid Diagnostics (LUCD) shares does the CMO report holding?

The Chief Medical Officer reports direct ownership of 650,000 shares of Lucid Diagnostics common stock. This total includes several restricted stock grants that vest on future dates and remain subject to forfeiture if the required service periods are not fully completed.

What restricted stock grants does the Lucid Diagnostics (LUCD) CMO have?

The CMO holds restricted stock granted under the 2018 Equity Plan: 200,000 shares awarded November 6, 2023, 150,000 shares awarded February 20, 2025, and 300,000 shares awarded February 20, 2026, each with a single future vesting date tied to continued service.

When do the Lucid Diagnostics (LUCD) CMO’s restricted shares vest?

The CMO’s restricted stock vests on three dates: November 6, 2026 for 200,000 shares, May 20, 2028 for 150,000 shares, and May 20, 2029 for 300,000 shares, assuming the required service periods are fully satisfied for each grant.

Are the Lucid Diagnostics (LUCD) CMO’s restricted shares subject to forfeiture?

Yes. All reported restricted stock awards are subject to forfeiture if the CMO does not complete the requisite service periods. Each grant has a single vesting date, and failure to meet service conditions can cause the unvested restricted shares to be lost.

Under what plan were the Lucid Diagnostics (LUCD) CMO’s restricted shares granted?

The restricted stock reported by the CMO was granted under Lucid Diagnostics’ 2018 Equity Plan. This plan provides equity-based compensation, and the reported awards include specified grant dates, single vesting dates, and forfeiture provisions tied to ongoing employment service requirements.